References
1. Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 2016;12:566-592
2. Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 2009;96:151-157
3. Coyne DW. Influence of industry on renal guideline development. Clin J Am Soc Nephrol 2007;2:3-7; discussion 13-14
4. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA. Types and Distribution of Payments From Industry to Physicians in 2015. JAMA 2017;317:1774-1784
5. National Health and Nutrition Examination Survey 2017–March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes. In National Health Statistics ReportsNational Center for Health S, Ed. Hyattsville, MD, http://dx.doi.org/10.15620/cdc:106273, 2021
6. Fang M, Wang D, Coresh J, Selvin E. Undiagnosed Diabetes in U.S. Adults: Prevalence and Trends. Diabetes Care 2022;45:1994-2002
7. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45:2753-2786
8. Irwig MS, Kyinn M, Shefa MC. Financial Conflicts of Interest Among Authors of Endocrine Society Clinical Practice Guidelines. J Clin Endocrinol Metab 2018;103:4333-4338
9. Liu JJ, Bell CM, Matelski JJ, Detsky AS, Cram P. Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study. BMJ 2017;359:j4619
10. Inoue K, Tsugawa Y, Mangione CM, Duru OK. Association between industry payments and prescriptions of long-acting insulin: An observational study with propensity score matching. PLOS Medicine 2021;18:e1003645
11. Inoue K, Figueroa JF, DeJong C, Tsugawa Y, Orav EJ, Shen C, Kazi DS. Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States. Circulation: Cardiovascular Quality and Outcomes 2021;14:e007521
12. Karanges EA, Ting N, Parker L, Fabbri A, Bero L. Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes. Aust J Gen Pract 2020;49:151-154
13. Natures of Payment [article online], 2023. Available from https://www.cms.gov/openpayments/natures-of-payment#:~:text=The%20Open%20Payments%20Program%20Year,medical%20supply%20or%20device%20loan. Accessed January 17 2023
14. Open Payments [article online], 2022. Available from https://www.cms.gov/OpenPayments/Data/Dataset-Downloads. Accessed April 13 2023
15. Brauer PR, Morse E, Mehra S. Industry Payments for Otolaryngology Research: A Four-Year Analysis of the Open Payments Database. Laryngoscope 2020;130:314-320
16. Ying X, Rosenblatt R, Fortune BE. Trends in Industry Payments to Gastroenterologists and Hepatologists in the United States From 2014 to 2020. Gastroenterology 2022;163:787-791
17. Sharrak A, Nguyen T, Karabon P. Industry Research Payments to Urologists: The First 5 Years of Open Payments Research Data. J Urol 2020;204:408-410
18. Murayama A, Kugo H, Saito Y, Saito H, Tanimoto T, Ozaki A. A Nine-year Investigation of Healthcare Industry Payments to Pulmonologists in the United States. Ann Am Thorac Soc 2023;
19. Murayama A, Kamamoto S, Kugo H, Saito H, Ozaki A. Research and Nonresearch Industry Payments to Nephrologists in the United States between 2014 and 2021. J Am Soc Nephrol 2023;
20. Feng H, Wu P, Leger M. Exploring the Industry-Dermatologist Financial Relationship: Insight From the Open Payment Data. JAMA Dermatol 2016;152:1307-1313
21. Annapureddy A, Murugiah K, Minges KE, Chui PW, Desai N, Curtis JP. Industry Payments to Cardiologists. Circ Cardiovasc Qual Outcomes 2018;11:e005016
22. Murayama A, Nakano K, Kamamoto S, Sato M, Saito H, Tanimoto T, Ozaki A. Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and 2020. Clin Microbiol Infect 2022;28:1655 e1651-1655 e1654
23. Kusumi E, Murayama A, Kamamoto S, Kawashima M, Yoshida M, Saito H, Sawano T, Yamashita E, Tanimoto T, Ozaki A. Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Blood Cancer J 2022;12:54
24. Putman MS, Goldsher JE, Crowson CS, Duarte-Garcia A. Industry Payments to Practicing US Rheumatologists, 2014-2019. Arthritis Rheumatol 2021;73:2138-2144
25. Murayama A, Kamamoto S, Saito H, Tanimoto T, Ozaki A. Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic. Ann Allergy Asthma Immunol 2022;129:635-636
26. Murayama A, Kamamoto S, Higuchi K, Shigeta H, Ozaki A. Trend in Industry Payments to Rheumatologists in the United States During the COVID-19 Pandemic Between 2013 and 2021. J Rheumatol 2023;50:575-577
27. Murayama A. Codes for analysis of Open Payments Database for Endocrinology, Diabetes & Metabolism. GitHub; 2023.https://github.com/anju0007/Open-Payments-Database-Analyses/tree/ad41d9ee888a0365106c34b31cabc000103a29cc/Endocrinology%2C%20Diabetes%20%26%20Metabolism. Updated August 2, 2023. Accessed August 2, 2023.
28. Inoue K, Blumenthal DM, Elashoff D, Tsugawa Y. Association between physician characteristics and payments from industry in 2015-2017: observational study. BMJ Open 2019;9:e031010
29. Ahlawat A, Narayanaswami P. Financial relationships between neurologists and industry: The 2015 Open Payments database. Neurology 2019;92:1006-1013
30. Ellison-Barnes A, Johnson S, Gudzune K. Trends in Obesity Prevalence Among Adults Aged 18 Through 25 Years, 1976-2018. JAMA 2021;326:2073-2074
31. Inoue K, Duru OK, Mangione CM, Tsugawa Y. Trends in Industry Payments to Physicians for Antihyperglycemic Therapies Between 2014 and 2018. J Gen Intern Med 2021;36:2492-2494
32. Moynihan R. Key opinion leaders: independent experts or drug representatives in disguise? BMJ 2008;336:1402-1403
33. Wright K, Meyers DE, Chisamore TM, McInnes MDF, Sismondo S, Gyawali B, Prasad V, Booth CM. Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians? JCO Oncology Practice 2022;18:e1164-e1169
34. Nusrat S, Syed T, Nusrat S, Chen S, Chen WJ, Bielefeldt K. Assessment of Pharmaceutical Company and Device Manufacturer Payments to Gastroenterologists and Their Participation in Clinical Practice Guideline Panels. JAMA Netw Open 2018;1:e186343
35. Vanood A, Sharrak A, Karabon P, Fahim DK. Industry-Sponsored Research Payments in Neurosurgery-Analysis of the Open Payments Database From 2014 to 2018. Neurosurgery 2021;88:E250-e258
36. Eloy JA, Kilic S, Yoo NG, McLeod T, Svider PF, Baredes S, Folbe AJ, Couldwell WT, Liu JK. Is Industry Funding Associated with Greater Scholarly Impact Among Academic Neurosurgeons? World Neurosurg 2017;103:517-525
37. Murayama A. Industry-sponsored research funding to infectious disease physicians in the United States between 2013 and 2021. Clin Microbiol Infect 2023;
38. Kalva P, Kakkilaya A, Mekala P, Cavdar IK, Patel M, Kooner KS. Trends and Characteristics of Industry Payments for Ophthalmology Research From 2014 to 2020. JAMA Ophthalmol 2022;140:1105-1109
39. Ahn R, Woodbridge A, Abraham A, Saba S, Korenstein D, Madden E, Boscardin WJ, Keyhani S. Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study. BMJ 2017;356:i6770
40. Khan NA, Nguyen CL, Khawar T, Spencer H, Torralba KD. Association of author’s financial conflict of interest with characteristics and outcome of rheumatoid arthritis randomized controlled trials. Rheumatology (Oxford) 2019;58:776-785
Table 1. Summary of annual general payments to endocrinologists excluding ownership and royalty payments between 2014 and 2022.